

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

ARTICLE IN PRESS

Public Health xxx (xxxx) xxx



Contents lists available at ScienceDirect

Public Health

journal homepage: www.elsevier.com/locate/puhe



Letter to the Editor

Encouraging the elderly in China to receive the COVID-19 vaccine is the next necessary step

Since December 2021, the Omicron variant of severe acute respiratory syndrome coronavirus 2 has quickly spread throughout the world and has also mutated rapidly. According to the World Health Organization, the Omicron subtype BA.5 has become the dominant strain worldwide. BA.5 has a strong level of immune escape and a high level of infectivity, which is likely to set off a new epidemic wave in the world. Data from 31 December 2021 to 6 July 2022 in Hong Kong showed that 95% of COVID-19 deaths occurred in people aged \geq 60 years. Moreover, the fatality rate of the unvaccinated elderly was extremely high, and the fatality rate of people aged \geq 80 years reached 16.32%.

Safe and effective vaccination is important for controlling the pandemic and reducing the severity and fatality rate of COVID-19 infection. Although the proportion of elderly people vaccinated in China is increasing, it is still not ideal in absolute numbers.³ In many Western countries, the full vaccination rate of people aged >60 years is as high as 85–90%.³ In contrast, the vaccination rate of the elderly in China is relatively low, although these individuals are at high risk and are in urgent need of vaccination to boost their immunity.⁴ There are two main reasons why the vaccination rate of the elderly in China has not yet reach optimal levels. First, the elderly with underlying diseases often have safety concerns, such as the potential for serious side effects.³ It is reassuring that recent studies have proved the safety of the inactivated vaccine for patients with liver cancer.⁵ Other studies have also found that side effects of the COVID-19 vaccines were usually only mild to moderate in severity, with relatively short durations.² Second, the elderly have concerns regarding the effectiveness of the COVID-19 vaccine.³ However, the latest evidence has been very encouraging, showing that three doses of vaccine resulted in higher neutralising antibody levels than two doses of vaccine in people aged ≥60 years. The third/booster dose significantly improved the level of neutralising antibody against both the Delta and Omicron variants.2

Overall, as severe acute respiratory syndrome coronavirus 2 continues to mutate, unvaccinated people, especially the elderly, will be at greater risk. Recent studies have demonstrated reassuring findings to address the concerns of the elderly population regarding the COVID-19 vaccine. However, more combined efforts by healthcare workers, policy makers and the media to encourage the uptake of COVID-19 vaccination in the elderly and other at-risk populations, such as those with autoimmune diseases and cancer, are urgently needed to restore 'prepandemic life'.

References

- WHO. WHO Director-General's opening remarks at the COVID-19 media briefing—12 July 2022. World Health Organization; 2022. Available from: https://www.who. int/director-general/speeches/detail/who-director-general-s-opening-remarksat-the-covid-19-media-briefing—12-july-2022. [Accessed 14 July 2022].
- Jin P, Li J, Guo X, Gou J, Hou L, Song Z, et al. Heterologous CoronaVac plus Ad5nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, noninferiority, randomized study. medRxiv 2022. https://doi.org/10.1101/2022.06. 03.22275983. 2022.06.03.22275983.
- Huo S. Why are Vulnerable Elderly people in China reluctant to get COVID-19 vaccine? China News Weekly; 2022. Available from: http://www.inewsweek.cn/ society/2022-06-14/15881.shtml. [Accessed 14 July 2022].
- CCTV. Why the emphasis on strengthening COVID-19 vaccination for the elderly?
 CCTV news; 2022. Available from: http://stdaily.com/index/kejixinwen/202205/ededcc4b404e4d58bbd5d2b1ec11cb14.shtml. [Accessed 14 July 2022].
- Qi X, Wang J, Zhang Q, Ai J, Liu C, Li Q, et al. Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): a multicenter prospective study. J Med Virol 2022. https://doi.org/10.1002/jmv.27992.

Ning Li

Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China

Qiwei Liang

Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China

Anhui Provincial Children's Hospital/Children's Hospital of Anhui Medical University, Hefei Anhui, 230051, PR China

Shaodi Ma

Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China

Scott Lowe, Rachel Bentley

College of Osteopathic Medicine, Kansas City University, 1750 Independence Ave, Kansas City, MO 64106, USA

John Patrick Nanola Uy

Infectious disease and international health, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon NH 03756, USA

Chenyu Sun*

AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago 60657, Illinois, USA

* Corresponding author.

E-mail address: drsunchenyu@yeah.net (C. Sun).

22 July 2022 Available online xxx

https://doi.org/10.1016/j.puhe.2022.08.011

0033-3506/© 2022 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.